METRO launches a driver-less route, Houston biotech company raises millions, and more quick innovation news. Courtesy of METRO

So much Houston innovation news — so little time. In order to help keep in touch with all the news happening among startups and technology in Houston, we're hitting the highlights in this innovation news roundup.

If you know of innovation-focused news happening, email me at natalie@innovationmap.com with the details and subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.


METRO launches a self-driving shuttle on Texas Southern University's campus

Courtesy of Metro

The first autonomous shuttle in Houston recently had its maiden voyage on Texas Southern University's campus. The route is a one-mile stretch that is called the "Tiger Walk.' The EasyMile shuttle can transport 12 passengers and is operated by First Transit. The project is a pilot program for METRO to see if it has successful applications in other public transportation efforts.

"When passengers board this all electric vehicle they will be riding into the future and experiencing a mode of transportation that in just a few years may become commonplace," says METRO Chair Carrin Patman in a release.

The first phase of the pilot kicked off June 5, as reported in a previous InnovationMap article.

After being deemed a hot tech company by Crunchbase, Data Gumbo grows its C-suite

Courtesy of Data Gumbo

In June, Data Gumbo was named among Crunchbase's top 50 hottest tech companies. The list looked for growing tech startups that have raised between $5 million and $20 million, with a recent round closing in the past six months. The Houston-based company closed its most recent round of $6 million in the spring.

Following the round completion, Data Gumbo's CEO, Andrew Bruce, noted the funds were intended to further develop the company's technology and grow the team. As of last week, Bruce made good on the promise and announced the company's new chief commercial officer, Sergio A. Tuberquia.

"As our new capital is being used to expand our commercial blockchain network, we are also expanding our internal teams to support our rapid global growth," says Bruce in a news release. "With Sergio joining to lead revenue efforts, this will further our company's mission to help oil and gas companies — and ultimately all industries -—realize greater efficiencies and cost savings in the supply chain. Sergio's mix of startup technology and oil and gas industry experience will greatly benefit Data Gumbo and its customers as the industry moves into digital oilfield solutions like blockchain."

Biotech company extends its Series D round to $43 million

Getty Images

Following a $20 million commitment from Sanford Health, Houston-based InGeneron Inc. has extended its Series D round to $43 million. The funds will go toward further developing the company's regenerative medicine and cell therapy. InGeneron currently has a clinical study for rotator cuff recovery.

The investment by South Dakota-based Sanford Health was announced in March, and last month, InGeneron made the call to expand the series.

"Sanford Health's continued support helps advance InGeneron's regenerative cell therapy into the expansive pivotal trial phase, a significant step toward bringing our therapy into the clinic," says Angelo Moesslang, CEO of InGeneron, in a release. "This is an exciting time for the company, as one of the largest health systems in the United States further affirms the potential of adipose-derived regenerative cell therapy, while we diligently work to make it available to patients."

Rice Business Plan winner to ring the Nasdaq bell

Courtesy of Rice University

The company that won the top prize at the Rice Business Plan Competition and walked away with almost $700,000 is claiming another one of its prizes. Vita Inclinata Technologies will ring the opening bell at Nasdaq on July 3.

The company, which created a technology to advance helicopter safety, will be represented by its CEO, Caleb Carr, and Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship, and Will Roper, the U.S. Air Force's assistant secretary for acquisition, will also attend. The livestream footage is available online, beginning at 8:30 am central.

Mercury Fund raising money

Texas Money

Getty Images

Crunchbase broke the news that Houston-based Mercury Fund has secured $82 million of its fourth fund, Mercury Fund Ventures IV, that will total $125 million, per a regulatory filing that PE Hub reported on. Mercury Fund refused to comment on the ongoing raise, but intends to release more information following the close, a representative confirmed to InnovationMap.

According to Crunchbase's proprietary data, it's the largest fund to date for the firm. The most recent fund closed in 2014 at $105 million. Mercury Fund specializes in SaaS, cloud, and data science technology, according to its website.

Rice University and Baylor College of Medicine researcher recognized

Courtesy of Rice University

Olga Dudchenko, a genomics researcher at Rice University and Baylor College of Medicine, been named to MIT Technology Review magazine's 2019 list of 35 Innovators Under 35.

Dudchenko, who is completing her postdoctoral fellowship at Rice's Center for Theoretical Biological Physics, has developed a method to sequence and assemble the genome of any organism for less than $1,000. Her process is comparable the that of the Human Genome Project, which cost $3 billion.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”